학술논문
Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
Document Type
Case Study
Author
Source
Subject
*EPSTEIN-Barr virus
*RITUXIMAB
*HODGKIN'S disease
*CANCER chemotherapy
*LYMPHOPROLIFERATIVE disorders
*RICHTER syndrome
*CHRONIC lymphocytic leukemia
*
*
*
*
*
*
Language
ISSN
0344-0338
Abstract
Anti-CD20-based chemo-immunotherapeutic regimens have been suggested to assist in the management of Epstein-Barr virus (EBV)-induced hemophagocytic lymphohistiocytosis (HLH) and EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD), by reducing EBV viral load and EBV-induced inflammation. Herein we report a fatal EBV-related HLH in the context of Hodgkin lymphoma (HL)-like Richter’s transformation of B chronic lymphocytic leukemia (B-CLL), two months after rituximab treatment. The complex balance between EBV driven T-cell stimulation and immunosuppressive therapy in the context of multiple immune deficits is discussed. [ABSTRACT FROM AUTHOR]